Nancy Draskovic, OD
Optometrist · Alexandria, VANPI 1588696165
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,149 of the $8,399 with a category attached, or 73.2%. 22 manufacturers reported payments, led by AbbVie at 37.3% of the total. 2025 is the largest year on record at $3,277, more than ten times the $176 reported in 2019. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $33.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Bausch & Lomb Americas Inc.$1K
- Sun Pharmaceutical Industries Inc.$1K
- Novartis$588
- Harrow Eye, LLC$382
- Alcon$378
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,25027%
- Food & beverage$6,14973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $3,135 |
| Bausch & Lomb Americas Inc. | 39 | $1,184 |
| Sun Pharmaceutical Industries Inc. | 41 | $1,029 |
| Novartis | 31 | $588 |
| Harrow Eye, LLC | 12 | $382 |
| Alcon | 11 | $378 |
| Kala Pharmaceuticals, Inc. | 14 | $343 |
| Oyster Point Pharma, Inc. | 19 | $334 |
| Tarsus Pharmaceuticals, Inc. | 9 | $228 |
| Dompe US, Inc. | 7 | $192 |
| Glaukos Corporation | 3 | $167 |
| Sight Sciences, Inc. | 4 | $129 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $60 |
| LKC Technologies, Inc. | 1 | $45 |
| Thea Pharma Inc. | 2 | $44 |
| Rayner Intraocular Lenses Limited | 2 | $36 |
| Rxsight Inc | 1 | $32 |
| Eyepoint US, Inc. | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| NEW World Medical,inc. | 1 | $18 |
| Quidel Corporation | 1 | $17 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,399 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 233 | $391,970 |
| RestasisCyclosporine | 118 | $166,604 |
| TyrvayaVarenicline Tartrate | 73 | $53,529 |
| CequaCyclosporine | 44 | $41,928 |
| Cyclosporine | 77 | $35,855 |
| LumiganBimatoprost | 53 | $32,195 |
| MieboPerfluorohexyloctane/Pf | 18 | $16,299 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $14,549 |
| Brimonidine Tartrate | 72 | $11,231 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $10,536 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 23 | $5,250 |
| Loteprednol Etabonate | 25 | $4,795 |
| Travoprost | 16 | $4,116 |
| Prednisolone Acetate | 60 | $4,094 |
| Latanoprost | 159 | $2,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,184 | $408,269251 claims |
| AbbVieRestasis, Lumigan, Combigan | $3,135 | $213,349196 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $334 | $53,52973 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,029 | $41,92844 claims |
| AlconSimbrinza | $378 | $5,25023 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $60 | $4,79525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.
Other optometrist in Alexandria
- Michelle leAlexandria$9K
- Walter WhitleyNorfolk$546K
- Jacqueline TheisRichmond$80K
- Joseph AllenRichmond$75K
- Keith SmithsonReston$74K
- Michael SwattsChesapeake$59K
- Kurt DevitoVirginia Beach$54K
- Walter SchlabachHarrisonburg$31K
- Mark AbrahamFalls Church$30K
- David TangVirginia Beach$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.